Molecular pathways: Targeting p21-activated kinase 1 signaling in cancer - Opportunities, challenges, and limitations

Clinical Cancer Research

Volumn 18, Issue 14, 2012, Pages 3750-3761

  Eswaran, Jeyanthy ^a,b   Li, Da Qiang ^b   Shah, Anil ^a   Kumar, Rakesh ^b,c  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1,1,' DINAPHTHYLDISULFIDE; 2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; CEP 1347; ESTROGEN RECEPTOR ALPHA; FL 172; MESSENGER RNA; MICRORNA; P21 ACTIVATED KINASE 1; PF 3758309; PROTEIN CDC42; PROTEIN KINASE INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG; P21 ACTIVATED KINASE; PAK1 PROTEIN, HUMAN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL SURVIVAL; CYTOSKELETON; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; IC 50; INTRACELLULAR SIGNALING; MALIGNANT TRANSFORMATION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PAK1 GENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; TRANSCRIPTION REGULATION; CELL TRANSFORMATION; DRUG ANTAGONISM; GENETICS; METABOLISM; NEOPLASM; PROGNOSIS; SIGNAL TRANSDUCTION;

CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; P21-ACTIVATED KINASES; PROGNOSIS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84863968373     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-1952     Document Type: Review

References (66)

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
2. Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in cancer. Nat Rev Cancer 2006;6:459-71.
3. Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem 2003;72:743-81. (Pubitemid 36930459)
4. Manser E, Leung T, Salihuddin H, Zhao ZS, Lim L. A brain serine/threonine protein kinase activated by Cdc42 and Rac1. Nature 1994;367:40-6. (Pubitemid 24038530)
5. Bokoch GM, Wang Y, Bohl BP, Sells MA, Quilliam LA, Knaus UG. Interaction of the Nck adapter protein with p21-activated kinase (PAK1). J Biol Chem 1996;271:25746-9. (Pubitemid 26347400)
6. Galisteo ML, Chernoff J, Su YC, Skolnik EY, Schlessinger J. The adaptor protein Nck links receptor tyrosine kinases with the serine-threonine kinase Pak1. J Biol Chem 1996;271:20997-1000. (Pubitemid 26292943)
7. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 1998;273:28238-46. (Pubitemid 28496122)
8. Ong CC, Jubb AM, Haverty PM, Zhou W, Tran V, Truong T, et al. Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A 2011;108:7177-82.
9. Arias-Romero LE, Villamar-Cruz O, Pacheco A, Kosoff R, Huang M, Muthuswamy SK, et al. A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells. Oncogene 2010;29:5839-49.
10. Janke C, Bulinski JC. Post-translational regulation of the microtubule cytoskeleton: mechanisms and functions. Nat Rev Mol Cell Biol 2011;12:773-86.
11. Manser E, Huang HY, Loo TH, Chen XQ, Dong JM, Leung T, et al. Expression of constitutively active alpha-PAK reveals effects of the kinase on actin and focal complexes. Mol Cell Biol 1997;17:1129-43. (Pubitemid 27097342)
12. Sells MA, Knaus UG, Bagrodia S, Ambrose DM, Bokoch GM, Chernoff J. Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells. Curr Biol 1997;7:202-10. (Pubitemid 27164726)
13. Vadlamudi RK, Li F, Barnes CJ, Bagheri-Yarmand R, Kumar R. p41-Arc subunit of human Arp2/3 complex is a p21-activated kinase-1-interacting substrate. EMBO Rep 2004;5:154-60. (Pubitemid 38401194)
14. Edwards DC, Sanders LC, Bokoch GM, Gill GN. Activation of LIMkinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cyto-skeletal dynamics. Nat Cell Biol 1999;1:253-9. (Pubitemid 129495774)
15. Vadlamudi RK, Li F, Adam L, Nguyen D, Ohta Y, Stossel TP, et al. Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1. Nat Cell Biol 2002;4:681-90. (Pubitemid 34993704)
16. Daub H, Gevaert K, Vandekerckhove J, Sobel A, Hall A. Rac/Cdc42 and p65PAK regulate the microtubule-destabilizing protein stathmin through phosphorylation at serine 16. J Biol Chem 2001;276:1677-80. (Pubitemid 32109635)
17. Vadlamudi RK, Barnes CJ, Rayala S, Li F, Balasenthil S, Marcus S, et al. p21-activated kinase 1 regulates microtubule dynamics by phosphorylating tubulin cofactor B. Mol Cell Biol 2005;25:3726-36. (Pubitemid 40559578)
18. Vadlamudi RK, Bagheri-Yarmand R, Yang Z, Balasenthil S, Nguyen D, Sahin AA, et al. Dynein light chain 1, a p21-activated kinase 1-interacting substrate, promotes cancerous phenotypes. Cancer Cell 2004;5:575-85. (Pubitemid 38748919)
19. Frost JA, Khokhlatchev A, Stippec S, White MA, Cobb MH. Differential effects of PAK1-activating mutations reveal activity-dependent and -independent effects on cytoskeletal regulation. J Biol Chem 1998;273:28191-8. (Pubitemid 28496117)
20. Adam L, Vadlamudi R, Mandal M, Chernoff J, Kumar R. Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. J Biol Chem 2000;275:12041-50. (Pubitemid 30237778)
21. Tang Y, Chen Z, Ambrose D, Liu J, Gibbs JB, Chernoff J, et al. Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol Cell Biol 1997;17:4454-64. (Pubitemid 27318122)
22. Tang Y, Zhou H, Chen A, Pittman RN, Field J. The Akt proto-oncogene links Ras to Pak and cell survival signals. J Biol Chem 2000;275:9106-9. (Pubitemid 30185123)
23. Scḧurmann A, Mooney AF, Sanders LC, Sells MA, Wang HG, Reed JC, et al. p21-activated kinase 1 phosphorylates the death agonist Bad and protects cells from apoptosis. Mol Cell Biol 2000;20:453-61.
24. Deacon K, Mistry P, Chernoff J, Blank JL, Patel R. p38 Mitogen-activated protein kinase mediates cell death and p21-activated kinase mediates cell survival during chemotherapeutic drug-induced mitotic arrest. Mol Biol Cell 2003;14:2071-87. (Pubitemid 36583554)
25. Frost JA, Swantek JL, Stippec S, Yin MJ, Gaynor R, Cobb MH. Stimulation of NFkappa B activity by multiple signaling pathways requires PAK1. J Biol Chem 2000;275:19693-9. (Pubitemid 30441565)
26. Wang RA, Zhang H, Balasenthil S, Medina D, Kumar R. PAK1 hyper-activation is sufficient for mammary gland tumor formation. Oncogene 2006;25:2931-6. (Pubitemid 43739243)
27. Liu Y, Xiao H, Tian Y, Nekrasova T, Hao X, Lee HJ, et al. The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice. Mol Cancer Res 2008;6:1215-24.
28. Vadlamudi RK, Adam L, Wang RA, Mandal M, Nguyen D, Sahin A, et al. Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem 2000;275:36238-44.
29. Balasenthil S, Sahin AA, Barnes CJ, Wang RA, Pestell RG, Vadlamudi RK, et al. p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem 2004;279:1422-8. (Pubitemid 38082670)
30. Li F, Adam L, Vadlamudi RK, Zhou H, Sen S, Chernoff J, et al. p21-activated kinase 1 interacts with and phosphorylates histone H3 in breast cancer cells. EMBO Rep 2002;3:767-73. (Pubitemid 34966016)
31. Zhao ZS, Lim JP, Ng YW, Lim L, Manser E. The GIT-associated kinase PAK targets to the centrosome and regulates Aurora-A. Mol Cell 2005;20:237-49. (Pubitemid 41484169)
32. Molli PR, Li DQ, Bagheri-Yarmand R, Pakala SB, Katayama H, Sen S, et al. Arpc1b, a centrosomal protein, is both an activator and substrate of Aurora A. J Cell Biol 2010;190:101-14.
33. Lightcap CM, Kari G, Arias-Romero LE, Chernoff J, Rodeck U, Williams JC. Interaction with LC8 is required for Pak1 nuclear import and is indispensable for zebrafish development. PLoS ONE 2009;4:e6025.
34. Singh RR, Song C, Yang Z, Kumar R. Nuclear localization and chromatin targets of p21-activated kinase 1. J Biol Chem 2005;280:18130-7. (Pubitemid 41397965)
35. Barnes CJ, Vadlamudi RK, Mishra SK, Jacobson RH, Li F, Kumar R. Functional inactivation of a transcriptional corepressor by a signaling kinase. Nat Struct Biol 2003;10:622-8. (Pubitemid 36944715)
36. Vadlamudi RK, Manavathi B, Singh RR, Nguyen D, Li F, Kumar R. An essential role of Pak1 phosphorylation of SHARP in Notch signaling. Oncogene 2005;24:4591-6. (Pubitemid 41032623)
37. Yang Z, Rayala S, Nguyen D, Vadlamudi RK, Chen S, Kumar R. Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions. Cancer Res 2005;65:3179-84. (Pubitemid 40524599)
38. Wang RA, Mazumdar A, Vadlamudi RK, Kumar R. P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J 2002;21:5437-47. (Pubitemid 35231023)
39. Balasenthil S, Barnes CJ, Rayala SK, Kumar R. Estrogen receptor activation at serine 305 is sufficient to upregulate cyclin D1 in breast cancer cells. FEBS Lett 2004;567:243-7. (Pubitemid 38748399)
40. Kok M, Zwart W, Holm C, Fles R, Hauptmann M, Van't Veer LJ, et al. PKA-induced phosphorylation of ERa at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer. Breast Cancer Res Treat 2011;125:1-12.
41. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K, et al. Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. Cancer Cell 2004;5:597-605. (Pubitemid 38748921)
42. Rayala SK, Talukder AH, Balasenthil S, Tharakan R, Barnes CJ, Wang RA, et al. P21-activated kinase 1 regulation of estrogen receptor-alpha activation involves serine 305 activation linked with serine 118 phosphorylation. Cancer Res 2006;66:1694-701. (Pubitemid 43259954)
43. Holm C, Rayala S, Jirstr̈om K, Stål O, Kumar R, Landberg G. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 2006;98:671-80. (Pubitemid 43821785)
44. Rayala SK, Kumar R. Sliding p21-activated kinase 1 to nucleus impacts tamoxifen sensitivity. Biomed Pharmacother 2007;61:408-11. (Pubitemid 47239343)
45. Bostner J, Ahnstr̈om Waltersson M, Fornander T, Skoog L, Nordenskj̈old B, Stål O. Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Oncogene 2007;26:6997-7005. (Pubitemid 350014611)
46. Bostner J, Skoog L, Fornander T, Nordenskj̈old B, Stål O. Estrogen receptor-alpha phosphorylation at serine 305, nuclear p21-activated kinase 1 expression, and response to tamoxifen in postmenopausal breast cancer. Clin Cancer Res 2010;16:1624-33.
47. Hirokawa Y, Arnold M, Nakajima H, Zalcberg J, Maruta H. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol Ther 2005;4:956-60. (Pubitemid 41598590)
48. Ching YP, Leong VY, Wong CM, Kung HF. Identification of an autoinhibitory domain of p21-activated protein kinase 5. J Biol Chem 2003;278:33621-4. (Pubitemid 37553193)
49. Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J, et al. An isoform-selective, small-molecule inhibitor targets the auto-regulatory mechanism of p21-activated kinase. Chem Biol 2008;15:322-31. (Pubitemid 351508427)
50. Lei M, Lu W, Meng W, Parrini MC, Eck MJ, Mayer BJ, et al. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell 2000;102:387-97.
51. Zenke FT, King CC, Bohl BP, Bokoch GM. Identification of a central phosphorylation site in p21-activated kinase regulating autoinhibition and kinase activity. J Biol Chem 1999;274:32565-73. (Pubitemid 129535281)
52. Wang J, Wu JW, Wang ZX. Structural insights into the autoactivation mechanism of p21-activated protein kinase. Structure 2011;19:1752-61.
53. Weisz Hubsman M, Volinsky N, Manser E, Yablonski D, Aronheim A. Autophosphorylation-dependent degradation of Pak1, triggered by the Rho-family GTPase, Chp. Biochem J 2007;404:487-97. (Pubitemid 46953923)
54. Kissil JL, Wilker EW, Johnson KC, Eckman MS, Yaffe MB, Jacks T. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol Cell 2003;12:841-9. (Pubitemid 37352778)
55. Deguchi A, Miyoshi H, Kojima Y, Okawa K, Aoki M, Taketo MM. LKB1 suppresses p21-activated kinase-1 (PAK1) by phosphorylation of Thr109 in the p21-binding domain. J Biol Chem 2010;285: 18283-90.
56. Talukder AH, Meng Q, Kumar R. CRIPak, a novel endogenous Pak1 inhibitor. Oncogene 2006;25:1311-9. (Pubitemid 43336459)
57. Alahari SK, Reddig PJ, Juliano RL. The integrin-binding protein Nischarin regulates cell migration by inhibiting PAK. EMBO J 2004;23:2777-88. (Pubitemid 39013550)
58. Reddy SD, Ohshiro K, Rayala SK, Kumar R. MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Res 2008;68:8195-200.
59. Saydam O, Senol O, Ẅurdinger T, Mizrak A, Ozdener GB, Stemmer-Rachamimov AO, et al. miRNA-7 attenuation in Schwannoma tumors stimulates growth by upregulating three oncogenic signaling pathways. Cancer Res 2011;71:852-61.
60. Zou J, Li WQ, Li Q, Li XQ, Zhang JT, Liu GQ, et al. Two functional microRNA-126s repress a novel target gene p21-activated kinase 1 to regulate vascular integrity in zebrafish. Circ Res 2011;108:201-9.
61. Nheu TV, He H, Hirokawa Y, Tamaki K, Florin L, Schmitz ML, et al. The K252a derivatives, inhibitors for the PAK/MLK kinase family selectively block the growth of RAS transformants. Cancer J 2002;8:328-36.
62. Porchia LM, Guerra M, Wang YC, Zhang Y, Espinosa AV, Shinohara M, et al. 2-amino-N-4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase. Mol Pharmacol 2007;72:1124-31. (Pubitemid 350012586)
63. Maksimoska J, Feng L, Harms K, Yi C, Kissil J, Marmorstein R, et al. Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. J Am Chem Soc 2008;130:15764-5.
64. Jha RK, Leaver-Fay A, Yin S, Wu Y, Butterfoss GL, Szyperski T, et al. Computational design of a PAK1 binding protein. J Mol Biol 2010;400:257-70.
65. Viaud J, Peterson JR. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol Cancer Ther 2009;8:2559-65.
66. Yi C, Maksimoska J, Marmorstein R, Kissil JL. Development of small-molecule inhibitors of the group I p21-activated kinases, emerging therapeutic targets in cancer. Biochem Pharmacol 2010;80:683-9.